Loading…
Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats
Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used for treatment of arthritis. However, their long-term use has been associated with considerable morbidity, limiting their application. Thus, there remains a need to develop new drugs for the effective and safe relief of chronic inflammato...
Saved in:
Published in: | European journal of pharmacology 2009-08, Vol.616 (1-3), p.91-100 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c412t-e36cda1b1e81bd3b98b6732e6f3c91be82f6c41a25367e783d9ffaf1383164123 |
---|---|
cites | cdi_FETCH-LOGICAL-c412t-e36cda1b1e81bd3b98b6732e6f3c91be82f6c41a25367e783d9ffaf1383164123 |
container_end_page | 100 |
container_issue | 1-3 |
container_start_page | 91 |
container_title | European journal of pharmacology |
container_volume | 616 |
creator | SAUZEM, Patricia D SANT'ANNA, Gabriela Da S RUBIN, Maribel A MACHADO, Pablo DUARTE, Marta M. M. F FERREIRA, Juliano MELLO, Carlos R BECK, Paulo BONACORSO, Helio G ZANATTA, Nilo MARTINS, Marcos A. P |
description | Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used for treatment of arthritis. However, their long-term use has been associated with considerable morbidity, limiting their application. Thus, there remains a need to develop new drugs for the effective and safe relief of chronic inflammatory pain. In this context, the present study was designed to evaluate the antinociceptive and antiedematogenic effects of the 5-trifluoromethyl-4,5-dihydro-1H-pyrazole derivatives EPFCA3 and MPFCA4 after acute (1-1000 micromol/kg) and chronic (100 micromol/kg for 15 days) administration in rats submitted to a model of adjuvant-induced arthritis. We also analyzed some biochemical indicators of toxicity (alanine aminotransferase, aspartate aminotransferase, urea and creatinine levels) after prolonged administration of these compounds. We found that acute and chronic subcutaneuous administration of EPFCA3 and MPFCA4 produces an antinociceptive, but not antiedematogenic, effect on the arthritis animal model induced by complete Freund's adjuvant (CFA). No signs of toxicity were observed in the animals chronically treated with EPFCA3 or MPFCA4. Dipyrone (1-1000 micromol/kg) was used as the positive control and its effect was similar to that of the novel pyrazoles. The activity of tissue myeloperoxidase, the tissue TNF-alpha level and the serum haptoglobin level was increased by intraplantar CFA injection. However, chronic administration of EPFCA3, MPFCA4 or dipyrone was not able to alter the relation between these parameters and inflammation. Our results suggest that EPFCA3 and MPFCA4 are good candidates for the development of new drugs for pain treatment. |
doi_str_mv | 10.1016/j.ejphar.2009.06.008 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20700769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20700769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-e36cda1b1e81bd3b98b6732e6f3c91be82f6c41a25367e783d9ffaf1383164123</originalsourceid><addsrcrecordid>eNpFkEtLxDAURoMoOj7-gUg3ujL13qRNm6WILxDc6DqkacJ0SJuadBb111uZQVcXLuc7i0PIJUKOgOJuk9vNuNYxZwAyB5ED1AdkhXUlKVTIDskKAAvKpJQn5DSlDQCUkpXH5ARlWQBjfEXUo3PWTFlwWUmn2Dm_DTH0dlrPnha3JW279dzGQPGFjnPU38HblIUhM-sYhs5k3eC87ns9hThno-6GrA-t9cs_i3pK5-TIaZ_sxf6ekc-nx4-HF_r2_vz6cP9GTYFsopYL02ps0NbYtLyRdSMqzqxw3EhsbM2cWEjNSi4qW9W8lc5ph7zmKBYDPyM3O-8Yw9fWpkn1XTLWez3YsE2KQQVQCbmAxQ40MaQUrVNj7HodZ4WgfsOqjdqFVb9hFQi1hF1mV3v_tult-z_al1yA6z2gk9HeRT2YLv1xDCXjC8p_AGVdgy8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20700769</pqid></control><display><type>article</type><title>Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats</title><source>Elsevier</source><creator>SAUZEM, Patricia D ; SANT'ANNA, Gabriela Da S ; RUBIN, Maribel A ; MACHADO, Pablo ; DUARTE, Marta M. M. F ; FERREIRA, Juliano ; MELLO, Carlos R ; BECK, Paulo ; BONACORSO, Helio G ; ZANATTA, Nilo ; MARTINS, Marcos A. P</creator><creatorcontrib>SAUZEM, Patricia D ; SANT'ANNA, Gabriela Da S ; RUBIN, Maribel A ; MACHADO, Pablo ; DUARTE, Marta M. M. F ; FERREIRA, Juliano ; MELLO, Carlos R ; BECK, Paulo ; BONACORSO, Helio G ; ZANATTA, Nilo ; MARTINS, Marcos A. P</creatorcontrib><description>Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used for treatment of arthritis. However, their long-term use has been associated with considerable morbidity, limiting their application. Thus, there remains a need to develop new drugs for the effective and safe relief of chronic inflammatory pain. In this context, the present study was designed to evaluate the antinociceptive and antiedematogenic effects of the 5-trifluoromethyl-4,5-dihydro-1H-pyrazole derivatives EPFCA3 and MPFCA4 after acute (1-1000 micromol/kg) and chronic (100 micromol/kg for 15 days) administration in rats submitted to a model of adjuvant-induced arthritis. We also analyzed some biochemical indicators of toxicity (alanine aminotransferase, aspartate aminotransferase, urea and creatinine levels) after prolonged administration of these compounds. We found that acute and chronic subcutaneuous administration of EPFCA3 and MPFCA4 produces an antinociceptive, but not antiedematogenic, effect on the arthritis animal model induced by complete Freund's adjuvant (CFA). No signs of toxicity were observed in the animals chronically treated with EPFCA3 or MPFCA4. Dipyrone (1-1000 micromol/kg) was used as the positive control and its effect was similar to that of the novel pyrazoles. The activity of tissue myeloperoxidase, the tissue TNF-alpha level and the serum haptoglobin level was increased by intraplantar CFA injection. However, chronic administration of EPFCA3, MPFCA4 or dipyrone was not able to alter the relation between these parameters and inflammation. Our results suggest that EPFCA3 and MPFCA4 are good candidates for the development of new drugs for pain treatment.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2009.06.008</identifier><identifier>PMID: 19540223</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier</publisher><subject>Alanine transaminase ; Analgesics - administration & dosage ; Analgesics - chemistry ; Analgesics - pharmacology ; Analgesics - therapeutic use ; Animals ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - chemistry ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Arthritis, Experimental - drug therapy ; Arthritis, Experimental - enzymology ; Arthritis, Experimental - metabolism ; Arthritis, Experimental - pathology ; Biological and medical sciences ; Body Weight - drug effects ; Chronic Disease - drug therapy ; Creatinine - blood ; Dipyrone - administration & dosage ; Dipyrone - pharmacology ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Edema - blood ; Edema - drug therapy ; Edema - enzymology ; Edema - pathology ; Haptoglobins - metabolism ; Inflammation - blood ; Inflammation - drug therapy ; Inflammation - enzymology ; Inflammation - pathology ; Leukocytes - drug effects ; Leukocytes - metabolism ; Male ; Medical sciences ; Organ Size - drug effects ; Pain - blood ; Pain - drug therapy ; Pain - enzymology ; Pain - pathology ; Pharmacology. Drug treatments ; Pyrazoles - administration & dosage ; Pyrazoles - chemistry ; Pyrazoles - pharmacology ; Pyrazoles - therapeutic use ; Rats ; Rats, Wistar ; Reference Standards ; Stomach - drug effects ; Stomach - pathology ; Time Factors ; Tumor Necrosis Factor-alpha - metabolism ; Urea - blood</subject><ispartof>European journal of pharmacology, 2009-08, Vol.616 (1-3), p.91-100</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-e36cda1b1e81bd3b98b6732e6f3c91be82f6c41a25367e783d9ffaf1383164123</citedby><cites>FETCH-LOGICAL-c412t-e36cda1b1e81bd3b98b6732e6f3c91be82f6c41a25367e783d9ffaf1383164123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21923540$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19540223$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SAUZEM, Patricia D</creatorcontrib><creatorcontrib>SANT'ANNA, Gabriela Da S</creatorcontrib><creatorcontrib>RUBIN, Maribel A</creatorcontrib><creatorcontrib>MACHADO, Pablo</creatorcontrib><creatorcontrib>DUARTE, Marta M. M. F</creatorcontrib><creatorcontrib>FERREIRA, Juliano</creatorcontrib><creatorcontrib>MELLO, Carlos R</creatorcontrib><creatorcontrib>BECK, Paulo</creatorcontrib><creatorcontrib>BONACORSO, Helio G</creatorcontrib><creatorcontrib>ZANATTA, Nilo</creatorcontrib><creatorcontrib>MARTINS, Marcos A. P</creatorcontrib><title>Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used for treatment of arthritis. However, their long-term use has been associated with considerable morbidity, limiting their application. Thus, there remains a need to develop new drugs for the effective and safe relief of chronic inflammatory pain. In this context, the present study was designed to evaluate the antinociceptive and antiedematogenic effects of the 5-trifluoromethyl-4,5-dihydro-1H-pyrazole derivatives EPFCA3 and MPFCA4 after acute (1-1000 micromol/kg) and chronic (100 micromol/kg for 15 days) administration in rats submitted to a model of adjuvant-induced arthritis. We also analyzed some biochemical indicators of toxicity (alanine aminotransferase, aspartate aminotransferase, urea and creatinine levels) after prolonged administration of these compounds. We found that acute and chronic subcutaneuous administration of EPFCA3 and MPFCA4 produces an antinociceptive, but not antiedematogenic, effect on the arthritis animal model induced by complete Freund's adjuvant (CFA). No signs of toxicity were observed in the animals chronically treated with EPFCA3 or MPFCA4. Dipyrone (1-1000 micromol/kg) was used as the positive control and its effect was similar to that of the novel pyrazoles. The activity of tissue myeloperoxidase, the tissue TNF-alpha level and the serum haptoglobin level was increased by intraplantar CFA injection. However, chronic administration of EPFCA3, MPFCA4 or dipyrone was not able to alter the relation between these parameters and inflammation. Our results suggest that EPFCA3 and MPFCA4 are good candidates for the development of new drugs for pain treatment.</description><subject>Alanine transaminase</subject><subject>Analgesics - administration & dosage</subject><subject>Analgesics - chemistry</subject><subject>Analgesics - pharmacology</subject><subject>Analgesics - therapeutic use</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - chemistry</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Arthritis, Experimental - drug therapy</subject><subject>Arthritis, Experimental - enzymology</subject><subject>Arthritis, Experimental - metabolism</subject><subject>Arthritis, Experimental - pathology</subject><subject>Biological and medical sciences</subject><subject>Body Weight - drug effects</subject><subject>Chronic Disease - drug therapy</subject><subject>Creatinine - blood</subject><subject>Dipyrone - administration & dosage</subject><subject>Dipyrone - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Edema - blood</subject><subject>Edema - drug therapy</subject><subject>Edema - enzymology</subject><subject>Edema - pathology</subject><subject>Haptoglobins - metabolism</subject><subject>Inflammation - blood</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - enzymology</subject><subject>Inflammation - pathology</subject><subject>Leukocytes - drug effects</subject><subject>Leukocytes - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Organ Size - drug effects</subject><subject>Pain - blood</subject><subject>Pain - drug therapy</subject><subject>Pain - enzymology</subject><subject>Pain - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazoles - administration & dosage</subject><subject>Pyrazoles - chemistry</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reference Standards</subject><subject>Stomach - drug effects</subject><subject>Stomach - pathology</subject><subject>Time Factors</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Urea - blood</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNpFkEtLxDAURoMoOj7-gUg3ujL13qRNm6WILxDc6DqkacJ0SJuadBb111uZQVcXLuc7i0PIJUKOgOJuk9vNuNYxZwAyB5ED1AdkhXUlKVTIDskKAAvKpJQn5DSlDQCUkpXH5ARlWQBjfEXUo3PWTFlwWUmn2Dm_DTH0dlrPnha3JW279dzGQPGFjnPU38HblIUhM-sYhs5k3eC87ns9hThno-6GrA-t9cs_i3pK5-TIaZ_sxf6ekc-nx4-HF_r2_vz6cP9GTYFsopYL02ps0NbYtLyRdSMqzqxw3EhsbM2cWEjNSi4qW9W8lc5ph7zmKBYDPyM3O-8Yw9fWpkn1XTLWez3YsE2KQQVQCbmAxQ40MaQUrVNj7HodZ4WgfsOqjdqFVb9hFQi1hF1mV3v_tult-z_al1yA6z2gk9HeRT2YLv1xDCXjC8p_AGVdgy8</recordid><startdate>20090815</startdate><enddate>20090815</enddate><creator>SAUZEM, Patricia D</creator><creator>SANT'ANNA, Gabriela Da S</creator><creator>RUBIN, Maribel A</creator><creator>MACHADO, Pablo</creator><creator>DUARTE, Marta M. M. F</creator><creator>FERREIRA, Juliano</creator><creator>MELLO, Carlos R</creator><creator>BECK, Paulo</creator><creator>BONACORSO, Helio G</creator><creator>ZANATTA, Nilo</creator><creator>MARTINS, Marcos A. P</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20090815</creationdate><title>Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats</title><author>SAUZEM, Patricia D ; SANT'ANNA, Gabriela Da S ; RUBIN, Maribel A ; MACHADO, Pablo ; DUARTE, Marta M. M. F ; FERREIRA, Juliano ; MELLO, Carlos R ; BECK, Paulo ; BONACORSO, Helio G ; ZANATTA, Nilo ; MARTINS, Marcos A. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-e36cda1b1e81bd3b98b6732e6f3c91be82f6c41a25367e783d9ffaf1383164123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Alanine transaminase</topic><topic>Analgesics - administration & dosage</topic><topic>Analgesics - chemistry</topic><topic>Analgesics - pharmacology</topic><topic>Analgesics - therapeutic use</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - chemistry</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Arthritis, Experimental - drug therapy</topic><topic>Arthritis, Experimental - enzymology</topic><topic>Arthritis, Experimental - metabolism</topic><topic>Arthritis, Experimental - pathology</topic><topic>Biological and medical sciences</topic><topic>Body Weight - drug effects</topic><topic>Chronic Disease - drug therapy</topic><topic>Creatinine - blood</topic><topic>Dipyrone - administration & dosage</topic><topic>Dipyrone - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Edema - blood</topic><topic>Edema - drug therapy</topic><topic>Edema - enzymology</topic><topic>Edema - pathology</topic><topic>Haptoglobins - metabolism</topic><topic>Inflammation - blood</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - enzymology</topic><topic>Inflammation - pathology</topic><topic>Leukocytes - drug effects</topic><topic>Leukocytes - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Organ Size - drug effects</topic><topic>Pain - blood</topic><topic>Pain - drug therapy</topic><topic>Pain - enzymology</topic><topic>Pain - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazoles - administration & dosage</topic><topic>Pyrazoles - chemistry</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reference Standards</topic><topic>Stomach - drug effects</topic><topic>Stomach - pathology</topic><topic>Time Factors</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Urea - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SAUZEM, Patricia D</creatorcontrib><creatorcontrib>SANT'ANNA, Gabriela Da S</creatorcontrib><creatorcontrib>RUBIN, Maribel A</creatorcontrib><creatorcontrib>MACHADO, Pablo</creatorcontrib><creatorcontrib>DUARTE, Marta M. M. F</creatorcontrib><creatorcontrib>FERREIRA, Juliano</creatorcontrib><creatorcontrib>MELLO, Carlos R</creatorcontrib><creatorcontrib>BECK, Paulo</creatorcontrib><creatorcontrib>BONACORSO, Helio G</creatorcontrib><creatorcontrib>ZANATTA, Nilo</creatorcontrib><creatorcontrib>MARTINS, Marcos A. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SAUZEM, Patricia D</au><au>SANT'ANNA, Gabriela Da S</au><au>RUBIN, Maribel A</au><au>MACHADO, Pablo</au><au>DUARTE, Marta M. M. F</au><au>FERREIRA, Juliano</au><au>MELLO, Carlos R</au><au>BECK, Paulo</au><au>BONACORSO, Helio G</au><au>ZANATTA, Nilo</au><au>MARTINS, Marcos A. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2009-08-15</date><risdate>2009</risdate><volume>616</volume><issue>1-3</issue><spage>91</spage><epage>100</epage><pages>91-100</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used for treatment of arthritis. However, their long-term use has been associated with considerable morbidity, limiting their application. Thus, there remains a need to develop new drugs for the effective and safe relief of chronic inflammatory pain. In this context, the present study was designed to evaluate the antinociceptive and antiedematogenic effects of the 5-trifluoromethyl-4,5-dihydro-1H-pyrazole derivatives EPFCA3 and MPFCA4 after acute (1-1000 micromol/kg) and chronic (100 micromol/kg for 15 days) administration in rats submitted to a model of adjuvant-induced arthritis. We also analyzed some biochemical indicators of toxicity (alanine aminotransferase, aspartate aminotransferase, urea and creatinine levels) after prolonged administration of these compounds. We found that acute and chronic subcutaneuous administration of EPFCA3 and MPFCA4 produces an antinociceptive, but not antiedematogenic, effect on the arthritis animal model induced by complete Freund's adjuvant (CFA). No signs of toxicity were observed in the animals chronically treated with EPFCA3 or MPFCA4. Dipyrone (1-1000 micromol/kg) was used as the positive control and its effect was similar to that of the novel pyrazoles. The activity of tissue myeloperoxidase, the tissue TNF-alpha level and the serum haptoglobin level was increased by intraplantar CFA injection. However, chronic administration of EPFCA3, MPFCA4 or dipyrone was not able to alter the relation between these parameters and inflammation. Our results suggest that EPFCA3 and MPFCA4 are good candidates for the development of new drugs for pain treatment.</abstract><cop>Amsterdam</cop><pub>Elsevier</pub><pmid>19540223</pmid><doi>10.1016/j.ejphar.2009.06.008</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2009-08, Vol.616 (1-3), p.91-100 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_20700769 |
source | Elsevier |
subjects | Alanine transaminase Analgesics - administration & dosage Analgesics - chemistry Analgesics - pharmacology Analgesics - therapeutic use Animals Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - chemistry Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Arthritis, Experimental - drug therapy Arthritis, Experimental - enzymology Arthritis, Experimental - metabolism Arthritis, Experimental - pathology Biological and medical sciences Body Weight - drug effects Chronic Disease - drug therapy Creatinine - blood Dipyrone - administration & dosage Dipyrone - pharmacology Disease Models, Animal Dose-Response Relationship, Drug Edema - blood Edema - drug therapy Edema - enzymology Edema - pathology Haptoglobins - metabolism Inflammation - blood Inflammation - drug therapy Inflammation - enzymology Inflammation - pathology Leukocytes - drug effects Leukocytes - metabolism Male Medical sciences Organ Size - drug effects Pain - blood Pain - drug therapy Pain - enzymology Pain - pathology Pharmacology. Drug treatments Pyrazoles - administration & dosage Pyrazoles - chemistry Pyrazoles - pharmacology Pyrazoles - therapeutic use Rats Rats, Wistar Reference Standards Stomach - drug effects Stomach - pathology Time Factors Tumor Necrosis Factor-alpha - metabolism Urea - blood |
title | Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A45%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%205-trifluoromethyl-4,5-dihydro-1H-pyrazoles%20on%20chronic%20inflammatory%20pain%20model%20in%20rats&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=SAUZEM,%20Patricia%20D&rft.date=2009-08-15&rft.volume=616&rft.issue=1-3&rft.spage=91&rft.epage=100&rft.pages=91-100&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/j.ejphar.2009.06.008&rft_dat=%3Cproquest_cross%3E20700769%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-e36cda1b1e81bd3b98b6732e6f3c91be82f6c41a25367e783d9ffaf1383164123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20700769&rft_id=info:pmid/19540223&rfr_iscdi=true |